Literature DB >> 28956335

Role of PDE9 in Cognition.

C Dorner-Ciossek1, K S Kroker2, H Rosenbrock2.   

Abstract

Inhibition of phosphodiesterases (PDEs) has been demonstrated to enhance performance of animals in various cognition tasks and accordingly PDE inhibitors have been proposed as new approach for treatment of cognitive dysfunction (Reneerkens et al. Psychopharmacology 202:419-443, 2009; Schmidt Curr Top Med Chem 10(2):222-230, 2010). One of the eleven PDE isoforms, showing expression in cognition relevant brain regions across species, is PDE9, which hydrolyzes cGMP only. Furthermore, it is well established that the nitric oxide (NO)/cGMP pathway and NMDA receptor signaling has a crucial function in synaptic plasticity and cognitive function. In this chapter, we will provide an overview on PDE9, its expression and function in the brain, and hence, its relevance for synaptic plasticity and cognitive performance. Moreover, the recent advances of PDE9 inhibition as potential therapeutic approach for treatment of cognitive dysfunction in CNS disorders will be discussed.

Entities:  

Keywords:  Behavior; Cognition; Enzyme; Inhibitor; LTP; PDE9

Mesh:

Substances:

Year:  2017        PMID: 28956335     DOI: 10.1007/978-3-319-58811-7_9

Source DB:  PubMed          Journal:  Adv Neurobiol


  6 in total

1.  Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders.

Authors:  Joseph Scarborough; Daniele Mattei; Cornelia Dorner-Ciossek; Michael Sand; Roberto Arban; Holger Rosenbrock; Juliet Richetto; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2021-05-03       Impact factor: 7.853

2.  cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development.

Authors:  Andreas Friebe; Peter Sandner; Achim Schmidtko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

Review 3.  Memory Enhancers for Alzheimer's Dementia: Focus on cGMP.

Authors:  Ernesto Fedele; Roberta Ricciarelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

4.  Phosphodiesterases Expression during Murine Cardiac Development.

Authors:  Thays Maria da Conceição Silva Carvalho; Silvia Cardarelli; Mauro Giorgi; Andrea Lenzi; Andrea M Isidori; Fabio Naro
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

5.  Methylxanthines: Potential Therapeutic Agents for Glioblastoma.

Authors:  Daniel Pérez-Pérez; Iannel Reyes-Vidal; Elda Georgina Chávez-Cortez; Julio Sotelo; Roxana Magaña-Maldonado
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-07

6.  Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Klaudia Chmielewska; Iwona Inkielewicz-Stepniak
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.